Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orient Europharma Co's Total Liabilities for the quarter that ended in Dec. 2025 was NT$4,854 Mil.
Orient Europharma Co's quarterly Total Liabilities
declined
from Jun. 2025 (NT$5,336.84 Mil) to Sep. 2025 (NT$4,536.96 Mil) but then
increased
from Sep. 2025 (NT$4,536.96 Mil) to Dec. 2025 (NT$4,854.26 Mil).
Orient Europharma Co's annual Total Liabilities
declined
from Dec. 2023 (NT$6,649.31 Mil) to Dec. 2024 (NT$5,745.86 Mil) and
declined
from Dec. 2024 (NT$5,745.86 Mil) to Dec. 2025 (NT$4,854.26 Mil).
Orient Europharma Co Total Liabilities Related Terms
Orient Europharma Co Total Liabilities Historical Data
* Premium members only.
The historical data trend for Orient Europharma Co's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Europharma Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Orient Europharma Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of NT$4,854 Mil mean?
Orient Europharma Co (ROCO:4120) has a Total Liabilities of NT$4,854 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Orient Europharma Co and its competitors.
Is Orient Europharma Co's Total Liabilities too high?
Orient Europharma Co's current Total Liabilities is NT$4,854 Mil. Overall, Orient Europharma Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's Total Liabilities compare to ZTS and UTHR?
Orient Europharma Co's Total Liabilities of NT$4,854 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Orient Europharma Co and its competitors. Orient Europharma Co's current Total Liabilities is NT$4,854 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$44.98, compared to a current price of NT$44.40 — trading 1.3% below its estimated fair value. The current Total Liabilities is NT$4,854 Mil. Orient Europharma Co's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current Total Liabilities is NT$4,854 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued.
The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98.
GuruFocus considers Orient Europharma Co to be Fairly Valued.
Key valuation signals for ROCO:4120:
Total Liabilities: NT$4,854 Mil
GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
61GF Score
Get the complete analysis for ROCO:4120
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4120 has been successfully added to your 
